2.2(top 20%)
impact factor
2.6K(top 10%)
papers
56.6K(top 5%)
citations
98(top 5%)
h-index
2.3(top 20%)
impact factor
3.1K
all documents
59.6K
doc citations
145(top 5%)
g-index

Top Articles

#TitleJournalYearCitations
1Phage Therapy in Clinical Practice: Treatment of Human InfectionsCurrent Pharmaceutical Biotechnology2010550
2Lantibiotics: Mode of Action, Biosynthesis and BioengineeringCurrent Pharmaceutical Biotechnology2009446
3Nutritional and Therapeutic Potential of SpirulinaCurrent Pharmaceutical Biotechnology2005376
4Ganoderma lucidum: A Potent Pharmacological MacrofungusCurrent Pharmaceutical Biotechnology2009343
5Phage Choice, Isolation, and Preparation for Phage TherapyCurrent Pharmaceutical Biotechnology2010334
6CAR T-cell Therapy: A New Era in Cancer ImmunotherapyCurrent Pharmaceutical Biotechnology2018321
7Essential Fatty Acids - A ReviewCurrent Pharmaceutical Biotechnology2006320
8Sports Medicine Applications of Platelet Rich PlasmaCurrent Pharmaceutical Biotechnology2012297
9Bacteriophage for Biocontrol of Foodborne Pathogens: Calculations and ConsiderationsCurrent Pharmaceutical Biotechnology2010286
10Cell Proliferation and Cytotoxicity AssaysCurrent Pharmaceutical Biotechnology2016284
11Do the Fibrin Architecture and Leukocyte Content Influence the Growth Factor Release of Platelet Concentrates? An Evidence-based Answer Comparing a Pure Platelet-Rich Plasma (P-PRP) Gel and a Leukocyte- and Platelet-Rich Fibrin (L-PRF)Current Pharmaceutical Biotechnology2012271
12Gamma Linolenic Acid: An Antiinflammatory Omega-6 Fatty AcidCurrent Pharmaceutical Biotechnology2006260
13A Review on the Toxicity and Non-Target Effects of Macrocyclic Lactones in Terrestrial and Aquatic EnvironmentsCurrent Pharmaceutical Biotechnology2012260
14The Impact of Nanobiotechnology on the Development of New Drug Delivery SystemsCurrent Pharmaceutical Biotechnology2005258
15Mechanisms of Protein AggregationCurrent Pharmaceutical Biotechnology2009246
16Editorial (Thematic Issue: “miRNA and Cancer; Computational and Experimental Approaches”)Current Pharmaceutical Biotechnology2014242
17Joint Diseases and Matrix Metalloproteinases: A Role for MMP-13Current Pharmaceutical Biotechnology2008241
18The Use of Phages for the Removal of Infectious BiofilmsCurrent Pharmaceutical Biotechnology2008239
19Immune Responses to Therapeutic Proteins in Humans - Clinical Significance, Assessment and PredictionCurrent Pharmaceutical Biotechnology2002239
20Monoclonal Antibodies as Innovative TherapeuticsCurrent Pharmaceutical Biotechnology2008235
21Marine Sponges: Potential Sources of New Antimicrobial DrugsCurrent Pharmaceutical Biotechnology2009229
22Application of Chitin and Chitosan Derivatives in the Pharmaceutical FieldCurrent Pharmaceutical Biotechnology2003228
23Heterogeneity of Monoclonal Antibodies Revealed by Charge-Sensitive MethodsCurrent Pharmaceutical Biotechnology2008228
24Trends in Glycosylation, Glycoanalysis and Glycoengineering of Therapeutic Antibodies and Fc-Fusion ProteinsCurrent Pharmaceutical Biotechnology2008228
25Nanotechnology on Duty in Medical ApplicationsCurrent Pharmaceutical Biotechnology2005219
26Curcumin and Liver Cancer: A ReviewCurrent Pharmaceutical Biotechnology2012218
27Phage Therapy PharmacologyCurrent Pharmaceutical Biotechnology2010214
28Modulating Poly (ADP-Ribose) Polymerase Activity: Potential for the Prevention and Therapy of Pathogenic Situations Involving DNA Damage and Oxidative StressCurrent Pharmaceutical Biotechnology2002212
29Effect of Additives on Protein AggregationCurrent Pharmaceutical Biotechnology2009211
30Current Knowledge and Perspectives for the Use of Platelet-Rich Plasma (PRP) and Platelet-Rich Fibrin (PRF) in Oral and Maxillofacial Surgery Part 2: Bone Graft, Implant and Reconstructive SurgeryCurrent Pharmaceutical Biotechnology2012210
31Structure-Function Relationships of the Non-Lanthionine-Containing Peptide (class II) Bacteriocins Produced by Gram-Positive BacteriaCurrent Pharmaceutical Biotechnology2009208
32The Potential of Microalgae for the Production of Bioactive Molecules of Pharmaceutical InterestCurrent Pharmaceutical Biotechnology2012201
33Current Knowledge and Perspectives for the Use of Platelet-Rich Plasma (PRP) and Platelet-Rich Fibrin (PRF) in Oral and Maxillofacial Surgery Part 1: Periodontal and Dentoalveolar SurgeryCurrent Pharmaceutical Biotechnology2012201
34In Search of a Consensus Terminology in the Field of Platelet Concentrates for Surgical Use: Platelet-Rich Plasma (PRP), Platelet-Rich Fibrin (PRF), Fibrin Gel Polymerization and LeukocytesCurrent Pharmaceutical Biotechnology2012197
35Lipid Metabolism During Pregnancy and its Implications for Fetal GrowthCurrent Pharmaceutical Biotechnology2014192
36Revisiting the ABCs of Multidrug Resistance in Cancer ChemotherapyCurrent Pharmaceutical Biotechnology2011185
37A Critical Review of Methods for Size Characterization of Non-Particulate Protein AggregatesCurrent Pharmaceutical Biotechnology2009180
38History of Avermectin and Ivermectin, with Notes on the History of Other Macrocyclic Lactone Antiparasitic AgentsCurrent Pharmaceutical Biotechnology2012179
39Mucopolysaccharidosis Type IVA (Morquio A Disease): Clinical Review and Current Treatment: A Special ReviewCurrent Pharmaceutical Biotechnology2011178
40Art and Artefacts of Fluorescence Correlation SpectroscopyCurrent Pharmaceutical Biotechnology2004177
41Biopharmaceutical Powders Particle Formation and Formulation ConsiderationsCurrent Pharmaceutical Biotechnology2000176
42From Production of Peptides in Milligram Amounts for Research to Multi-Tons Quantities for Drugs of the FutureCurrent Pharmaceutical Biotechnology2004174
43Spirulina in Health Care ManagementCurrent Pharmaceutical Biotechnology2008174
44DNAzymes: From Creation In Vitro to Application In VivoCurrent Pharmaceutical Biotechnology2004171
45Polyphenols: Well Beyond The Antioxidant Capacity: Gallic Acid and Related Compounds as Neuroprotective Agents: You are What You Eat!Current Pharmaceutical Biotechnology2014171
46Monitoring Cell Therapy Using Iron Oxide MR Contrast AgentsCurrent Pharmaceutical Biotechnology2004169
47Phage Therapy for Plant Disease ControlCurrent Pharmaceutical Biotechnology2010168
48Crocetin: an Agent Derived from Saffron for Prevention and Therapy for CancerCurrent Pharmaceutical Biotechnology2012168
49Silymarin in the Prevention and Treatment of Liver Diseases and Primary Liver CancerCurrent Pharmaceutical Biotechnology2012167
50Pharmacological Inhibitors of Fatty Acid Synthase (FASN)-Catalyzed Endogenous Fatty Acid Biogenesis: A New Family of Anti-Cancer Agents?Current Pharmaceutical Biotechnology2006163